# Amgen to acquire Horizon Therapeutics for $27.8 billion

Amgen announced a cash offer to acquire Horizon Therapeutics plc for $116.50 per share, valuing the company at approximately $27.8 billion on a fully diluted basis, with an enterprise value of about $28.3 billion.

- Type: Acquisition
- Announced: 2022-12-12
- Where: Ireland
- Value: $27.8B
- Status: announced
- Products: therapeutics
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Amgen](https://endata.com/companies/21121.md) (acquirer)
- [Horizon Therapeutics](https://endata.com/companies/67257.md) (target)

## Sources

- [amgen.com](https://www.amgen.com/newsroom/press-releases/2022/12/rule-2-7-announcement-amgen-inc-to-acquire-horizon-therapeutics-plc), 2022-12-12: "The Acquisition values the entire issued and to be issued ordinary share capital of the Company at approximately $27.8 billion on a fully diluted basis."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.